BMP/retinoic acid inducible neural specific 2Genealiases: DBCCR1L2 · FAM5B
Q-omics provides the consensus-scored BRINP2 profile across patient tissues and cancer cell-line models. BRINP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BRINP2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, BRINP2 RNA expression shows 13,031 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where BRINP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRINP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRINP2 survival associations across molecular data types. BRINP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRINP2 RNA expression–survival associations across cancer types. High BRINP2 expression shows unfavorable associations in KIRP and THYM, but favorable associations in MESO, PAAD, BRCA and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for BRINP2 RNA expression.
This table summarizes BRINP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BRINP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRINP2 shows lower tumor expression in COAD, LIHC, HNSC and BRCA and higher tumor expression in THCA and KIRP. The COAD box plot shows higher BRINP2 RNA expression in normal versus tumor tissue (log2 FC = −0.185, t-test p < 0.001).
This table shows molecular features associated with BRINP2 in patient tissues and cancer cell lines. In patient samples, BRINP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BRINP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
